首页 | 本学科首页   官方微博 | 高级检索  
检索        

前列地尔治疗糖尿病合并慢性肾脏病的临床疗效分析
引用本文:曾斯璐,陈思静,符海清.前列地尔治疗糖尿病合并慢性肾脏病的临床疗效分析[J].糖尿病新世界,2021(5):153-155.
作者姓名:曾斯璐  陈思静  符海清
作者单位:湛江市第一中医医院药学部
摘    要:目的探讨对糖尿病合并慢性肾脏病患者实施前列地尔治疗的临床疗效。方法从2018年1月—2019年12月择取80例糖尿病合并慢性肾脏病患者,将其随机分组研究,对照组(40例)实施左卡尼汀治疗,研究组(40例)实施前列地尔治疗,对比分析两组临床效果。结果治疗后研究组空腹血糖、糖化血红蛋白水平均低于对照组,差异有统计学意义(P<0.05);治疗后研究组总胆固醇、三酰甘油均低于对照组,差异有统计学意义(P<0.05);治疗后研究组血尿素氮、肌酐、尿蛋白排泄率均低于对照组,差异有统计学意义(P<0.05);治疗后研究组凝血酶时间、纤维蛋白原水平、凝血酶原时间均少于对照组,差异有统计学意义(P<0.05);两组不良反应对比差异无统计学意义(P>0.05)。结论对于糖尿病合并慢性肾脏病患者来说,前列地尔治疗可改善血糖、血脂,还可以改善肾功能及凝血功能,具备良好安全性,临床价值显著。

关 键 词:前列地尔  糖尿病  慢性肾脏病  血糖  血脂  肾功能

Analysis on the Clinical Efficacy of Alprostadil in the Treatment of Diabetes Mellitus Complicated with Chronic Kidney Disease
ZENG Silu,CHEN Sijing,FU Haiqing.Analysis on the Clinical Efficacy of Alprostadil in the Treatment of Diabetes Mellitus Complicated with Chronic Kidney Disease[J].Diabetes New World,2021(5):153-155.
Authors:ZENG Silu  CHEN Sijing  FU Haiqing
Institution:(Department of Pharmacy,Zhanjiang First Hospital of Traditional Chinese Medicine,Zhanjiang,Guangdong Province,524034 China)
Abstract:Objective To explore the clinical efficacy of alprostadil treatment in patients with diabetes and chronic kidney disease.Methods From January 2018 to December 2019,80 patients with diabetes and chronic kidney disease were selected and randomly divided into groups for study.The control group(40 cases)received levocarnitine treatment,and the study group(40 cases)received the alprostadil treatment.The clinical effects of the two groups were compared and analyzed with diltiazem.Results After treatment,the fasting blood glucose and glycosylated hemoglobin levels of the study group were lower than those of the control group,and the difference was statistically significant(P<0.05);after treatment,the total cholesterol and triglycerides of the study group were lower than those of the control group,and the difference was statistically significant(P<0.05);the excretion rates of blood urea nitrogen,creatinine,and urine protein in the study group after treatment were lower than those of the control group,and the difference was statistically significant(P<0.05);after treatment,the study group's thrombin time,fibrinogen level,and thrombin the original time was less than the control group,and the difference was statistically significant(P<0.05);the difference between the two groups of adverse reactions was not statistically significant(P>0.05).Conclusion For patients with diabetes and chronic kidney disease,alprostadil treatment can improve blood glucose,blood lipids,renal function and blood coagulation function,has good safety,and has significant clinical value.
Keywords:Alprostadil  Diabetes  Chronic kidney disease  Blood glucose  Blood lipids  Renal function
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号